Research programme: skin disorder therapeutics - Afecta Pharmaceuticals

Drug Profile

Research programme: skin disorder therapeutics - Afecta Pharmaceuticals

Alternative Names: AFX 210; AFX 2101; AFX 272; AFX 2721; AFX 372; AFX 3721

Latest Information Update: 03 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Afecta Pharmaceuticals
  • Class Anti-inflammatories; Skin disorder therapies; Small molecules
  • Mechanism of Action CCR2 receptor antagonists; Chemokine CCL2 inhibitors; Interleukin 13 inhibitors; Interleukin 4 inhibitors; Thymic stromal lymphopoietin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Skin disorders

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top